Skip to main content
. Author manuscript; available in PMC: 2023 Oct 20.
Published in final edited form as: N Engl J Med. 2022 Jun 5;387(6):495–505. doi: 10.1056/NEJMoa2203478

Figure 1. Response to Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma.

Figure 1.

Panel A shows the rates of stringent complete response, complete response (CR), very good partial response (VGPR), and partial response in 165 patients who were treated with teclistamab. A stringent complete response was defined as a complete response with a normal serum free light-chain ratio and an absence of clonal plasma cells on immunohistochemical analysis or negative two-color to four-color flow cytometry. Differences in percentage totals are due to rounding. Responses were assessed by an independent review committee with a cutoff date of March 16, 2022. Panel B shows responses over time in the 104 patients who had an overall response (partial response or better) among the 165 patients treated at the recommended phase 2 dose.